<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <p class="gem-c-title__context">
      Guidance
    </p>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Guidance on handling of Decentralised and Mutual Recognition Procedures in a no-deal Brexit
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph ">
    This guidance describes the approach the MHRA intends to take for products approved or pending in decentralised procedure (DCP) or mutual recognition procedures (MRP) if there is no-deal Brexit.
  </p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 18 March 2019
    <br></br>Last updated 8 August 2019
      — <a href="#history">see all updates</a>
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>




<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav role="navigation" class="gem-c-contents-list gem-c-contents-list--no-underline " data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#products-approved-in-dcpmrp-on-or-before-exit-day-with-the-uk-as-rms-or-cms" data-track-options="{"dimension29":"Products approved in DCP/MRP on or before exit day with the UK as RMS or CMS\n"}" href="#products-approved-in-dcpmrp-on-or-before-exit-day-with-the-uk-as-rms-or-cms">Products approved in DCP/MRP on or before exit day with the UK as RMS or CMS
</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#applications-pending-in-dcpmrp-with-the-uk-as-rms-or-cms-where-the-procedure-has-been-positively-finalised-on-or-before-exit-day-but-the-national-uk-licence-has-not-yet-been-granted" data-track-options="{"dimension29":"Applications pending in DCP/MRP with the UK as RMS or CMS where the procedure has been positively finalised on or before exit day but the national (UK) licence has not yet been granted"}" href="#applications-pending-in-dcpmrp-with-the-uk-as-rms-or-cms-where-the-procedure-has-been-positively-finalised-on-or-before-exit-day-but-the-national-uk-licence-has-not-yet-been-granted">Applications pending in DCP/MRP with the UK as RMS or CMS where the procedure has been positively finalised on or before exit day but the national (UK) licence has not yet been granted</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#applications-pending-in-dcp-with-the-uk-as-rms-or-cms-where-the-procedure-has-ended-with-a-negative-decision-on-or-before-exit-day" data-track-options="{"dimension29":"Applications pending in DCP with the UK as RMS or CMS, where the procedure has ended with a negative decision on or before exit day"}" href="#applications-pending-in-dcp-with-the-uk-as-rms-or-cms-where-the-procedure-has-ended-with-a-negative-decision-on-or-before-exit-day">Applications pending in DCP with the UK as RMS or CMS, where the procedure has ended with a negative decision on or before exit day</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 4" data-track-label="#applications-pending-in-dcp-with-the-uk-as-rms-or-cms-where-the-procedure-has-not-been-finalised-on-or-before-exit-day" data-track-options="{"dimension29":"Applications pending in DCP with the UK as RMS or CMS where the procedure has not been finalised on or before exit day"}" href="#applications-pending-in-dcp-with-the-uk-as-rms-or-cms-where-the-procedure-has-not-been-finalised-on-or-before-exit-day">Applications pending in DCP with the UK as RMS or CMS where the procedure has not been finalised on or before exit day</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 5" data-track-label="#for-a-procedure-where-the-uk-is-the-rms-and-leading-on-the-assessment-of-the-application" data-track-options="{"dimension29":"For a procedure where the UK is the RMS and leading on the assessment of the application"}" href="#for-a-procedure-where-the-uk-is-the-rms-and-leading-on-the-assessment-of-the-application">For a procedure where the UK is the RMS and leading on the assessment of the application</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 6" data-track-label="#for-a-procedure-where-the-uk-is-a-cms-and-not-leading-on-the-assessment-of-the-application" data-track-options="{"dimension29":"For a procedure where the UK is a CMS and not leading on the assessment of the application"}" href="#for-a-procedure-where-the-uk-is-a-cms-and-not-leading-on-the-assessment-of-the-application">For a procedure where the UK is a CMS and not leading on the assessment of the application</a>
        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed ">
          <a class="gem-c-contents-list__link " data-track-category="contentsClicked" data-track-action="content_item 7" data-track-label="#applications-pending-in-mrp-with-the-uk-as-cms-where-the-procedure-has-not-been-finalised-on-exit-day" data-track-options="{"dimension29":"Applications pending in MRP with the UK as CMS where the procedure has not been finalised on exit day"}" href="#applications-pending-in-mrp-with-the-uk-as-cms-where-the-procedure-has-not-been-finalised-on-exit-day">Applications pending in MRP with the UK as CMS where the procedure has not been finalised on exit day</a>
        </li>
    </ol>
  </nav>

      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<p>At the end of a decentralised procedure with a positive agreement, a national Marketing Authorisation (<abbr title="Marketing Authorisation">MA</abbr>) is issued in all Member States involved. For mutual recognition procedures where the UK is the Reference Member State (<abbr title="Reference Member State">RMS</abbr>), a national (UK) <abbr title="Marketing Authorisation">MA</abbr> has already been granted in the UK before the start of the <abbr title="Mutual Recognition Procedures">MRP</abbr>. For an <abbr title="Mutual Recognition Procedures">MRP</abbr> where the UK is a concerned Member State (<abbr title="Concerned Member State">CMS</abbr>), a national (UK) <abbr title="Marketing Authorisation">MA</abbr> is issued if a positive outcome is reached.</p>

<h2 id="products-approved-in-dcpmrp-on-or-before-exit-day-with-the-uk-as-rms-or-cms">Products approved in <abbr title="Decentralised Procedure">DCP</abbr>/<abbr title="Mutual Recognition Procedures">MRP</abbr> on or before exit day with the UK as <abbr title="Reference Member State">RMS</abbr> or <abbr title="Concerned Member State">CMS</abbr>
</h2>

<p>All medicinal products approved in the UK on or before the day the UK leaves the EU via a <abbr title="Decentralised Procedure">DCP</abbr> or <abbr title="Mutual Recognition Procedures">MRP</abbr> have been issued with a national (UK) <abbr title="Marketing Authorisation">MA</abbr>. These MAs will be unaffected and remain valid in the UK. Any subsequent variation to the <abbr title="Marketing Authorisation">MA</abbr> should be submitted as a national variation using current procedures (see separate guidance on variations) .</p>

<h2 id="applications-pending-in-dcpmrp-with-the-uk-as-rms-or-cms-where-the-procedure-has-been-positively-finalised-on-or-before-exit-day-but-the-national-uk-licence-has-not-yet-been-granted">Applications pending in <abbr title="Decentralised Procedure">DCP</abbr>/<abbr title="Mutual Recognition Procedures">MRP</abbr> with the UK as <abbr title="Reference Member State">RMS</abbr> or <abbr title="Concerned Member State">CMS</abbr> where the procedure has been positively finalised on or before exit day but the national (UK) licence has not yet been granted</h2>

<p>All ongoing <abbr title="Decentralised Procedure">DCP</abbr>/<abbr title="Mutual Recognition Procedures">MRP</abbr> procedures that are positively finalised on or before the day the UK leaves the EU, but are in the 30-day national phase of the procedure, will continue to be processed and issued with a national (UK) <abbr title="Marketing Authorisation">MA</abbr> in conformity with the approved assessment report, the summary of product characteristics and the labelling and package leaflet. Any subsequent variation to the <abbr title="Marketing Authorisation">MA</abbr> should be submitted as a national variation.</p>

<h2 id="applications-pending-in-dcp-with-the-uk-as-rms-or-cms-where-the-procedure-has-ended-with-a-negative-decision-on-or-before-exit-day">Applications pending in <abbr title="Decentralised Procedure">DCP</abbr> with the UK as <abbr title="Reference Member State">RMS</abbr> or <abbr title="Concerned Member State">CMS</abbr>, where the procedure has ended with a negative decision on or before exit day</h2>

<p>All ongoing <abbr title="Decentralised Procedure">DCP</abbr> procedures which are negatively concluded on or before the day the UK leaves the EU will be refused and no national (UK) <abbr title="Marketing Authorisation">MA</abbr> will be issued.</p>

<h2 id="applications-pending-in-dcp-with-the-uk-as-rms-or-cms-where-the-procedure-has-not-been-finalised-on-or-before-exit-day">Applications pending in <abbr title="Decentralised Procedure">DCP</abbr> with the UK as <abbr title="Reference Member State">RMS</abbr> or <abbr title="Concerned Member State">CMS</abbr> where the procedure has not been finalised on or before exit day</h2>

<p>For all ongoing DCPs with the UK as an <abbr title="Reference Member State">RMS</abbr> or <abbr title="Concerned Member State">CMS</abbr> in progress on or before the day the UK leaves the EU, and which have not reached the decision phase, the MHRA will complete the assessment as a national procedure. The MHRA will take into account any assessment that has already been reported by the <abbr title="Reference Member State">RMS</abbr> or <abbr title="Concerned Member States">CMSs</abbr> including any points raised.</p>

<p>The MHRA will determine the application as soon as reasonably practicable and will take all reasonable steps to ensure that it makes a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> in the time period that would have applied to that application on the date on which the application was submitted in <abbr title="Decentralised Procedure">DCP</abbr>. However, the need for a full assessment may mean that this is not possible.</p>

<p>No additional or different fee will be charged for an application already submitted and ongoing in <abbr title="Decentralised Procedure">DCP</abbr> that is completed as a national procedure.</p>

<h3 id="action-to-take-if-the-applicant-does-not-wish-to-continue-with-the-dcp-as-a-national-application">Action to take if the applicant does not wish to continue with the <abbr title="Decentralised Procedure">DCP</abbr> as a national application</h3>

<p>The applicant should notify the licensing authority in writing that they no longer want the application to proceed. A partial fee refund may be applicable in line with the current MHRA fees regulations.</p>

<h2 id="for-a-procedure-where-the-uk-is-the-rms-and-leading-on-the-assessment-of-the-application">For a procedure where the UK is the <abbr title="Reference Member State">RMS</abbr> and leading on the assessment of the application</h2>

<p>The following will apply depending on the stage of the procedure on exit date:</p>

<ul>
  <li>
    <p>for procedures which have started, but before Day 70, the MHRA will follow the agreed <abbr title="Decentralised Procedure">DCP</abbr> timetable and the assessment report will be available by Day 70. The assessment of the response to the Day 70 questions will follow the national procedure, and MHRA will make a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> before the end of 210 days.</p>
  </li>
  <li>
    <p>for procedures after circulation of the Day 70 assessment report but before Day 106 of the procedure, the assessment of the response to the Day 70 questions, and any <abbr title="Concerned Member State">CMS</abbr> comments that may have been received, will follow the national procedure and the MHRA will make a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> before the end of 210 days.</p>
  </li>
  <li>
    <p>for procedures after Day 105, the MHRA will follow the agreed <abbr title="Decentralised Procedure">DCP</abbr> timetable and will make a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> before the end of 210 days.</p>
  </li>
</ul>

<h2 id="for-a-procedure-where-the-uk-is-a-cms-and-not-leading-on-the-assessment-of-the-application">For a procedure where the UK is a <abbr title="Concerned Member State">CMS</abbr> and not leading on the assessment of the application</h2>

<p>The following will apply depending on the stage of the procedure on exit date.</p>

<ul>
  <li>
    <p>for procedures before circulation of the <abbr title="Reference Member State">RMS</abbr> Day 70 assessment report, it will be necessary for the MHRA to do a full assessment of the application. A revised timetable will be issued, and the application will follow the national procedure and timelines. The MHRA will endeavour to complete the procedure within the period of 210 days from the date of submission of the application in the <abbr title="Decentralised Procedure">DCP</abbr>, but the need for the full assessment may mean that this is not possible.</p>
  </li>
  <li>
    <p>for procedures after circulation of the <abbr title="Reference Member State">RMS</abbr> Day 70 assessment report but before Day 105 of the procedure, the MHRA will consider the <abbr title="Reference Member State">RMS</abbr> assessment that has already taken place. Any additional questions that MHRA needs to be addressed will be sent to the applicant within the timetable agreed for the <abbr title="Decentralised Procedure">DCP</abbr>. The assessment of the response will follow the national procedure, and the MHRA will make a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> before the end of 210 days.</p>
  </li>
  <li>
    <p>for procedures after Day 105 and before circulation of the <abbr title="Reference Member State">RMS</abbr> Day 120 assessment report, it will be necessary for the MHRA to do a full assessment of the response to the <abbr title="Reference Member State">RMS</abbr> Day 70 questions and any additional questions raised by the MHRA (and other <abbr title="Concerned Member State">CMS</abbr>). The assessment of the response will follow the national procedure, and the MHRA will make a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> before the end of 210 days.</p>
  </li>
  <li>
    <p>for procedures after circulation of the <abbr title="Reference Member State">RMS</abbr> Day 120 assessment report, the MHRA will consider the <abbr title="Reference Member State">RMS</abbr> assessment that has already taken place and any additional questions that MHRA needs to be addressed will be sent to the applicant within the timetable agreed for the <abbr title="Decentralised Procedure">DCP</abbr>. The assessment of the response will follow the national procedure, and the MHRA will make a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> before the end of 210 days.</p>
  </li>
</ul>

<h2 id="applications-pending-in-mrp-with-the-uk-as-cms-where-the-procedure-has-not-been-finalised-on-exit-day">Applications pending in <abbr title="Mutual Recognition Procedures">MRP</abbr> with the UK as <abbr title="Concerned Member State">CMS</abbr> where the procedure has not been finalised on exit day</h2>

<p>For all pending MRPs with the UK as <abbr title="Concerned Member State">CMS</abbr> in progress immediately before the day the UK leaves the EU, and which have not reached the decision phase, the MHRA will complete the assessment as a national procedure. The MHRA will take into account any assessment that has already been reported by the <abbr title="Reference Member State">RMS</abbr> or <abbr title="Concerned Member State">CMS</abbr> including any points raised. The MHRA will determine the application as soon as reasonably practicable and will take all reasonable steps to ensure that it makes a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> in the time period that would have applied to that application on the date on which the application was submitted.</p>

<p>No additional or different fee will be charged for an application already submitted and ongoing in <abbr title="Mutual Recognition Procedures">MRP</abbr> that is completed as a national procedure.</p>

<h3 id="action-to-take-if-the-applicant-does-not-wish-to-continue-with-the-mrp-as-a-national-application">Action to take if the applicant does not wish to continue with the <abbr title="Mutual Recognition Procedures">MRP</abbr> as a national application</h3>

<p>The applicant should notify the licensing authority in writing that they no longer want the application to proceed. A partial fee refund may be applicable in line with the <a href="https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees">current MHRA fees regulations</a>.</p>

<p>The following will apply depending on the stage of the procedure on exit day.</p>

<ul>
  <li>
    <p>for procedures before Day 30, the MHRA will consider the <abbr title="Reference Member State">RMS</abbr> assessment report circulated and any additional questions that MHRA needs to be addressed will be sent to the applicant by Day 30. The assessment of the response will follow the national procedure and the MHRA will make a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> before the end of 90 days.</p>
  </li>
  <li>
    <p>for procedures after Day 30, it will be necessary for the MHRA to do a full assessment of the response to any additional questions raised by the MHRA. The assessment of the response will follow the national procedure and the MHRA will make a decision to grant or refuse a UK <abbr title="Marketing Authorisation">MA</abbr> before the end of 90 days.</p>
  </li>
</ul>

<p>Applications submitted in <abbr title="Decentralised Procedure">DCP</abbr> or <abbr title="Mutual Recognition Procedures">MRP</abbr> with the UK as <abbr title="Reference Member State">RMS</abbr> or <abbr title="Concerned Member State">CMS</abbr> where the procedure has not been started on exit day.</p>

<p>For <abbr title="Decentralised Procedure">DCP</abbr> or <abbr title="Mutual Recognition Procedures">MRP</abbr> procedures that have been submitted to the UK but not started before exit day these will continue as national procedures. Once the application is considered valid, the procedure will start. The MHRA will endeavour to complete the procedure within the period of 210 days from the date of submission of a valid application in the <abbr title="Mutual Recognition Procedures">MRP</abbr>/<abbr title="Decentralised Procedure">DCP</abbr> procedure, but the need for the full assessment may mean that this is not possible.</p>

<p>No additional or different fee will be charged for an application already submitted before exit day and that is to be processed as a national procedure.</p>

<h3 id="action-to-take-if-the-applicant-does-not-wish-to-continue-with-the-procedure-as-a-national-application">Action to take if the applicant does not wish to continue with the procedure as a national application</h3>

<p>The applicant should notify the licensing authority in writing that they no longer want the application to proceed. A partial fee refund may be applicable in line with the <a href="https://www.gov.uk/government/publications/mhra-fees/current-mhra-fees">current MHRA fees regulations</a>.</p>

<h3 id="contact">Contact</h3>
<p>For specific queries please contact <a href="mailto:RIS.NA@mhra.gov.uk">RIS.NA@mhra.gov.uk</a>.</p>

<div class="call-to-action">
<h3 id="stay-up-to-date">Stay up to date</h3>

<p>This page tells you what to do if you the UK leaves the EU without a deal. It will be updated if anything changes, including if a deal is agreed.</p>

<p><a href="https://www.gov.uk/email-signup/?topic=/government/brexit">Sign up to email alerts</a> to get the latest information</p>
</div>

<p>This guidance will apply from exit day in line with the <a rel="external" href="http://www.legislation.gov.uk/uksi/2019/775/contents/made">Human Medicines Regulations (Amendment etc.) (EU Exit) Regulations 2019</a>.</p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates app-c-published-dates--history" id="history" data-module="toggle" lang="en">
    Published 18 March 2019
    <br></br>Last updated 8 August 2019
      <a href="#full-history" class="app-c-published-dates__toggle" data-controls="full-history" data-expanded="false" data-toggled-text="- hide all updates">+ show all updates</a>
      <div class="app-c-published-dates__change-history js-hidden" id="full-history">
        <ol>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-08-08T15:03:23.000+01:00">8 August 2019</time>
              We have restructured content to emphasise the actions applicants need to take at different stages, and removed some outdated background information.
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-03-18T13:56:00.000+00:00">18 March 2019</time>
              First published.
            </li>
        </ol>
      </div>
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">

    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-da535f1b" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-related_items-da535f1b" data-module="gem-toggle">


  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar  gem-c-related-navigation__section-link--other" data-track-category="relatedLinkClicked" data-track-action="1.1 Related content" data-track-label="/find-eu-exit-guidance-business" data-track-options="{"dimension28":"1","dimension29":"Find Brexit guidance for your business"}" href="/find-eu-exit-guidance-business">Find Brexit guidance for your business</a></li>

  </ul>
</nav>



      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-da535f1b" data-module="gem-toggle">

    <h3 id="related-nav-collections-da535f1b" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="2.1 Collection" data-track-label="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario" data-track-options="{"dimension28":"1","dimension29":"MHRA guidance and publications about a possible no deal Brexit"}" href="/government/collections/mhra-guidance-and-publications-on-a-possible-no-deal-scenario">MHRA guidance and publications about a possible no deal Brexit</a></li>

  </ul>
</nav>

  </div>


</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-aed5aff1" data-module="gem-toggle">

    <h2 id="related-nav-topics-aed5aff1" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"1","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>